NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
38 hedge funds and large institutions have $1.43M invested in NKGen Biotech, Inc. Warrants in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
19% more funds holding
Funds holding: 32 → 38 (+6)
6% less capital invested
Capital invested by funds: $1.52M → $1.43M (-$96.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$41.1K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$12.6K |
| 3 |
Jane Street
New York
|
+$8.41K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.04K |
| 5 |
ETH
Exos TFP Holdings
New York
|
+$4.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$29K |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$7K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
-$3.36K |
| 4 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
-$1.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CH
26
CVI Holdings
Wilmington,
Delaware
| $2.55K | – | – | – |
|
|
ACM
27
Atalaya Capital Management
New York
| $2.4K | – | – | – |
|
28
JP Morgan Chase
New York
| $2K | – | – | – |
|
|
SC
29
Sculptor Capital
New York
| $1.75K | – | – | – |
|
|
GF
30
Gabelli Funds
Rye,
New York
| $1.71K | -$3.36K | -40,000 | -67% |
|
|
BI
31
Bulldog Investors
Saddle Brook,
New Jersey
| $1.7K | +$1.68K | +20,000 | New |
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.58K | +$1.57K | +18,648 | New |
|
|
GCIA
33
Gabelli & Co Investment Advisers
Rye,
New York
| $1.46K | – | – | – |
|
34
Walleye Capital
New York
| $1.2K | +$326 | +3,881 | +38% |
|
|
SIA
35
Schechter Investment Advisors
Birmingham,
Michigan
| $958 | +$947 | +11,279 | New |
|
|
PI
36
PEAK6 Investments
Chicago,
Illinois
| $938 | – | – | – |
|
|
CCM
37
CAAS Capital Management
New York
| $849 | – | – | – |
|
|
MF
38
Magnetar Financial
Evanston,
Illinois
| – | -$29K | -200,000 | Closed |
|
|
FTCM
39
Fir Tree Capital Management
New York
| – | -$7K | -49,160 | Closed |
|
NKGNW Hedge Fund Activity: Q4 2022 in Review
38 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q4 2022, worth a combined $1.43M — down 6.3% from $1.52M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NKGNW positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Rivernorth Capital Management, adding an estimated $41.1K. The largest seller was Magnetar Financial, exiting entirely with an estimated $29K sold.
- 38 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q4 2022, up from 32 in Q3 2022.
- Funds reported $1.43M of NKGen Biotech, Inc. Warrants stock for Q4 2022, down 6.3% quarter-over-quarter.
- 9 funds opened new NKGen Biotech, Inc. Warrants positions in Q4 2022 and 2 closed out, a net change of +7 holders.
- The largest NKGen Biotech, Inc. Warrants buyer in Q4 2022 was Rivernorth Capital Management, an estimated $41.1K added.
- The largest NKGen Biotech, Inc. Warrants seller in Q4 2022 was Magnetar Financial, an estimated $29K sold.
Based on aggregated 13F filings for Q4 2022.